CONTINGENT VALUE RIGHTS AGREEMENTContingent Value Rights Agreement • January 28th, 2010 • Ligand Pharmaceuticals Inc • Pharmaceutical preparations • New York
Contract Type FiledJanuary 28th, 2010 Company Industry JurisdictionTHIS CONTINGENT VALUE RIGHTS AGREEMENT, dated as of January 27, 2010 (this “Agreement”, is entered into by and among Ligand Pharmaceuticals Incorporated, a Delaware corporation (“Buyer”), Metabasis Therapeutics, Inc., a Delaware corporation (“Target”), David F. Hale, as Stockholders’ Representative (the “Stockholders’ Representative”), and Mellon Investor Services LLC, a New Jersey limited liability company, as Rights Agent (the “Rights Agent”) and as initial General CVR Registrar (as defined herein).
Form of General CVR Agreement CONTINGENT VALUE RIGHTS AGREEMENTContingent Value Rights Agreement • October 28th, 2009 • Ligand Pharmaceuticals Inc • Pharmaceutical preparations • New York
Contract Type FiledOctober 28th, 2009 Company Industry JurisdictionTHIS CONTINGENT VALUE RIGHTS AGREEMENT, dated as of [ • ] (this “Agreement”, is entered into by and among Ligand Pharmaceuticals Incorporated, a Delaware corporation (“Buyer”), Metabasis Therapeutics, Inc., a Delaware corporation (“Target”), David F. Hale, as Stockholders’ Representative (the “Stockholders’ Representative”), and Mellon Investor Services LLC, a New Jersey limited liability company, as Rights Agent (the “Rights Agent”) and as initial General CVR Registrar (as defined herein).